CORCEPT THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
CORCEPT THERAPEUTICS INC. - More news...
CORCEPT THERAPEUTICS INC. - More news...
- NATIONALLY RANKED ROSEN LAW FIRM Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT
- INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
- Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
- Corcept Therapeutics Provides Miricorilant Clinical Development Update
- Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
- Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
- Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Therapeutics Announces Appointment of Three Senior Leaders
- Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain
- Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer
- Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update
- Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT
- Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer
- Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer
- Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares
- CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Inc. on Behalf of Corcept Stockholders and Encourages Investors to Contact the Firm
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT
- Corcept Therapeutics Announces Extension of Previously Announced Tender Offer
- Corcept Therapeutics to Present at Upcoming Investor Conferences